Cannabis for MS spasticity was associated with meaningful symptom improvement in a new meta-analysis involving 2,544 multiple sclerosis patients across nine trials. The strongest benefits emerged with longer treatment duration, while short-term effects were more modest. The findings may reshape how clinicians counsel patients about expectations, timing, and long-term cannabinoid therapy for neurological symptoms.